Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
10,710 total articles
Princeton Bancorp director Stephen Shueh bought a total of 10,500 common shares in two transactions, bringing his direct stake to 42,038 shares. The purchases, totaling $297,395, occurred on May 15, 2023 and May 3, 2024. The company also announced a quarterly cash dividend of $0.35 per share payable February 27, 2026 to holders of record on Februar…
Scynexis INC Chief Executive Officer David Angulo Gonzalez purchased 108,695 shares at $0.92 per unit in a private placement on April 1, 2026, and received warrants for an equal number of shares. The move accompanies a planned roughly $40 million financing, recent clinical-stage milestones for SCY-247 and analyst price targets in the $3 to $4 range…
Comstock Inc. director Leo M. Drozdoff purchased 28,000 shares on March 30, 2026, spending roughly $84,000. The acquisition comes as the recycler and metals-focused company reports a negative gross profit margin and recent balance-sheet adjustments, including an amendment to a promissory note with Georges Trust and a reported doubling of its asset …
Luminus Management LLC, a roughly 10% holder and director at Battalion Oil Corp (BATL), sold 1,890,481 common shares across March 30-31, 2026, realizing about $8.6 million. The activity included conversion of preferred stock into common shares and the relinquishment of cash-settled total return swap rights. The transactions occurred as the company’…
Slide Insurance Holdings Inc. (SLDE) President and COO Shannon Lucas sold 38,686 shares under a prearranged 10b5-1 plan between March 30 and April 1, 2026, generating roughly $700,004. The filings also show Lucas exercised stock options for 45,838 shares at no cost on March 31, 2026, and relinquished 9,019 shares to satisfy tax obligations. After t…
Slide Insurance Holdings Chief Executive Bruce Lucas sold 381,855 shares of common stock between March 30 and April 1, 2026, generating about $7.07 million through trades executed under a 10b5-1 plan. On March 31 he also sold 9,019 shares to meet tax obligations and exercised 22,919 RSUs at $0 per share. The company recently reported robust fourth-…
John P. Schmid, a director at AnaptysBio (ANAB), sold 20,645 shares of common stock on March 30, 2026, for a total of $1.16 million across multiple transactions. The company is proceeding with the spinout of First Tracks Biotherapeutics, which has secured $80 million in a private placement ahead of a planned distribution on April 20, 2026, and Anap…
Matthew Paul Larson, Chief Risk Officer at Slide Insurance Holdings (NASDAQ: SLDE), sold 11,250 shares on March 30, 2026, for $202,500 and simultaneously exercised and sold 11,250 options at $0.79 each. The trades were executed under a pre-arranged 10b5-1 plan adopted December 4, 2025. Slide reported robust fourth-quarter 2025 earnings and announce…
Alset International Ltd sold 100,390 shares of HWH International Inc on March 30, 2026 at a weighted average price of $0.983, generating $98,683 in proceeds. The sale left Alset International Limited with an indirect holding of 1,891,279 HWH shares. Separately, HWH has agreed to buy 99.55% of Hapi Metaverse Inc for $19.9 million via a five-year pro…
Christopher Longhito, Senior Vice President and Chief Supply Chain Officer at Global Industrial Co (NASDAQ: GIC), sold a total of $385,013 in common stock across multiple transactions from March 23 to March 27, 2026. On March 27 he also exercised options that cost $131,775. Following the reported trades and exercises, Longhito is listed as owning z…
Trupanion Inc.’s Chief Operating Officer John R. Gallagher sold 430 shares on March 30, 2026, at $25.47 per share, yielding $10,952. The transaction, executed under a Rule 10b5-1 trading plan adopted on August 20, 2025, leaves Gallagher with 31,957 shares. The stock is trading near its 52-week low of $24.32 and is down 41% over the past six months.…
Karen Krasney, Executive Vice President and General Counsel of Capricor Therapeutics (NASDAQ: CAPR), sold 25,000 shares on March 31, 2026 for $752,935 and simultaneously exercised options to acquire 25,000 shares. The disposal was carried out under a pre-established 10b5-1 trading plan. Capricor recently reported a Q4 fiscal 2025 EPS miss and conti…
Capricor Therapeutics CFO Anthony Bergmann sold 25,000 shares on March 31, 2026, under a 10b5-1 plan for roughly $753,152 and exercised options to acquire 25,000 shares at $3.18 each. The moves come as the company faces an earnings shortfall, analyst price targets that exceed current trading levels, and an upcoming PDUFA date for deramiocel.
A director of RH sold 11,000 shares on March 31, 2026, generating roughly $1.5 million in proceeds across multiple trades. The director also exercised options to acquire 11,000 shares at $39.42. The moves come as RH stock has fallen sharply over the past year and several brokerages have trimmed price targets following disappointing quarterly result…
Capricor Therapeutics director Sabar Karimah Es sold a combined 115,000 shares of common stock in two trades totaling about $3.5 million, after exercising options to acquire the same number of shares at $4.86 each. The sales, executed under a 10b5-1 plan adopted in December 2025, took place March 31 and April 1, 2026. The company recently reported …
Universal Safety Products, Inc. (NASDAQ: UUU) disclosed that director Ault Milton C III purchased shares totaling $72,808 across transactions on March 30 and 31. The company also reported issuing 405,000 shares between January 26 and February 3 as part of a convertible note conversion totaling $1,503,424.80, executed under a Section 4(a)(2) exempti…
Steven S. Fendley, President of Kratos Defense & Security Solutions' U.S. division, sold 6,998 shares of the company's common stock on March 30, 2026, realizing about $487,119. The transactions occurred under a 10b5-1 trading plan adopted May 12, 2025. The move comes as Kratos shares have fallen 15% over the prior week but remain up 131% year-over-…
MediaAlpha director Steven Yi reported the sale of 12,000 shares of Class A common stock across three trades from March 30 to April 1, 2026, raising $111,907. The transactions, disclosed on a Form 4 filing, were executed under a Rule 10b5-1 trading plan to cover tax liabilities from vested restricted stock units. The company recently posted Q4 2025…
Caddis Holdings, LP, a roughly 10% shareholder in Fermi Inc. (FRMI), disposed of 11,000,000 shares of common stock in two transactions on March 30 and March 31, 2026, generating approximately $56,268,500. The sales occurred as Fermi's shares experienced pronounced volatility, falling 19% over the prior week and 83% over the trailing year. Following…
Realty Income Corp director Gregory McLaughlin sold 3,275 shares on April 1, 2026, for $61.87 apiece, totaling $202,624. The transaction leaves McLaughlin with 34,993 shares held by a family trust. The REIT, with a market value of $57.86 billion and a 5.25% dividend yield, is trading above its InvestingPro Fair Value. Separately, the company priced…
Cheniere Energy EVP and CFO Zach Davis sold 29,000 shares of common stock on March 30, 2026, for $300 per share, a transaction valued at $8.7 million. After the sale Davis holds 87,146 shares. Independent valuation commentary cites potential overvaluation versus Fair Value despite a P/E of 11.38. Separately, Cheniere reported strong fourth-quarter …
Tesla director Kathleen Wilson-Thompson sold 20,008 shares on March 30, 2026 for roughly $9.27 million and exercised options to acquire 40,000 additional shares at $14.99 each. The transactions leave her with 47,748 shares directly owned. The moves occur amid divergent analyst price targets and commentary on deliveries and regional demand.
Elena Ridloff, a director at Kymera Therapeutics, sold 12,000 shares of the company's common stock on March 31 and April 1, 2026, for just over $1 million. The transactions, reported on a Form 4 with the SEC, occurred at prices between $85.1946 and $86.05. On those same dates she exercised options to buy 12,000 shares at $14.18 per share. Separatel…
Kymera Therapeutics Chief Operating Officer Jeremy G. Chadwick sold 22,240 shares across March 31 and April 1, 2026, for about $1.9 million, executing trades under a pre-arranged Rule 10b5-1 plan. The transactions coincided with a year of strong stock performance and followed option exercises that acquired the same number of shares at a strike of $…
C3.ai Chief Executive Officer Stephen Bradley Ehikian sold 52,194 Class A shares on March 31 for roughly $429,092, trimming his direct stake to 721,485 shares. The transactions coincide with the stock trading close to its 52-week low and follow disappointing quarterly results and lowered guidance that prompted multiple analyst target cuts.
